EpicentRx
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, EpicentRx sits in the top decile of US sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count).
EpicentRx: 15 sponsored US clinical trials, 2 recruiting.
EpicentRx sponsors 15 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 7 completed. 2 of these trials are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Carcinoma, Small Cell Lung, with 1 trials.
Top-decile sponsor footprint
EpicentRx ranks in the top decile of sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
7 of 12 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (58.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
15 total, page 1 of 1
RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer
NCT05966194
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
NCT04673942
A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer
NCT05566041
RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors
NCT04525014
RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer
NCT03699956
Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers
NCT03515538
RRx-001 + Radiation + Temozolomide In Newly Diagnosed Glioblastoma and Anaplastic Gliomas
NCT02871843
RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)
NCT02801097
A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab
NCT02518958
RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy
NCT02452970
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
NCT02489903
Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases
NCT02215512
A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer
NCT02096354
A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001
NCT02096341
Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects
NCT01359982
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 6 |
| Phase 3 | 2 |
Therapeutic Areas
What is open in the EpicentRx pipeline
2 recruiting of 15 indexed (13% open); 7 completed (47%).
Phase mix: 2 late (III/IV) vs 13 early (I/II) (early-phase heavy).
Top condition: Carcinoma, Small Cell Lung (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
EpicentRx: open-pipeline peers nationwide
Peers matched on 15 registered trials and 13% open enrollment, not the therapeutic-area sidebar.
EpicentRx sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 15 trials (± recruiting share)
- Allakos · 15 trials · 0% recruiting
- Arbor Research Collaborative for Health · 15 trials · 33% recruiting
- Arena Pharmaceuticals · 15 trials · 0% recruiting
- Arrowhead Pharmaceuticals · 15 trials · 20% recruiting
Sponsors near 13% open enrollment (± trial volume)
- Chiesi Farmaceutici S.p.A. · 13% recruiting · 30 trials
- Dizal Pharmaceuticals · 13% recruiting · 15 trials
- Edgewise Therapeutics · 13% recruiting · 15 trials
- European Organisation for Research and Treatment of Cancer - EORTC · 13% recruiting · 15 trials
Related
What to do with this EpicentRx page
15 registered trials is a research-attention snapshot, not an endorsement of EpicentRx or any single study.
- 2 of EpicentRx's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Carcinoma, Small Cell Lung is the condition EpicentRx studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Carcinoma, Small Cell Lung trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
EpicentRx pipeline card: 15 registered trials from official public datasets.Report a data error.